EUCTR2016-001676-29-NO进行中（未招募）1 期
PROMO: A phase II study of Pembrolizumab in patients with Relapsed Or Metastatic Osteosarcoma not eligible for curative surgery - PROMO
Oslo University Hospital (OUS)0 个研究点目标入组 25 人开始时间: 2016年9月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically confirmed osteosarcoma.
- •2. Disease relapse or progression after at least one line of systemic treatment.
- •3. Surgical resection with curative intent not possible.
- •4. Be willing and able to provide written informed consent/assent for the trial.
- •5. Be 18 years of age on day of signing informed consent.
- •6. Have measurable disease based on RECIST, version 1.1.
- •7. Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion.
- •8. Have a performance status of 0 or 1 on the ECOG Performance Scale.
- •9. Demonstrate adequate organ function as defined in Table 1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- •2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- •3. Has a known history of active TB (Bacillus Tuberculosis)
- •4. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.Hypersensitivity to pembrolizumab or any of its excipients.
- •5. Hypersensitivity to pembrolizumab or any of its excipients.
- •6. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
- •7. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent.
- •8. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
- •9. Has known active central nervous system (CNS) metastases and/or sarcomatous meningitis.
- •10. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
- •11. Has known history of, or any evidence of active, non-infectious pneumonitis.
- •12. Has an active infection requiring systemic therapy.
- •13. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.
- •14. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •15. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
- •16. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
- •17. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- •18. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- •19. Has received a live vaccine within 30 days of planned start of study therapy.
研究者
相似试验
进行中（未招募）
1 期
PROMO: A phase II study of Pembrolizumab in patients with Relapsed Or Metastatic Osteosarcoma not eligible for curative surgeryEUCTR2016-001676-29-ITOSLO UNIVERSITETSSYKEHUS HF25
进行中（未招募）
1 期
A phase II trial of MK-3475 in patients with non-small cell lung cancer with a performance status of 2non small cell lung cancer (NSCLC)MedDRA version: 18.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002241-55-GBniversity of Birmingham
招募中
不适用
A Prospective Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma After Failure of Platinum- and Mitotane-Based Chemotherapy (ACCOMPLISH)NeoplasmsKCT0006789ational Cancer Center30
招募中
2 期
Randomized Phase II, 2-arm study of Pembrolizumab after high dose radiation (SBRT) versus Pembrolizumab alone in patients with advanced non-small cell lung cancer.Non small cell lung cancer10038666lung cancerNL-OMON44895Antoni van Leeuwenhoek Ziekenhuis74
进行中（未招募）
1 期
Pembrolizumab after high dose radiation versus Pembrolizumab alone in patients with non-small cell lung cancer.Advanced non-small cell lung cancerMedDRA version: 19.0Level: LLTClassification code 10025048Term: Lung cancer non-small cell recurrentSystem Organ Class: 100000004864EUCTR2014-005118-49-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis